The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
India sales grew 23.5% YoY with consolidation of Wockhardt products
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The government has taken all the effective measures to make healthcare affordable
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated
